<code id='A2CA7E933E'></code><style id='A2CA7E933E'></style>
    • <acronym id='A2CA7E933E'></acronym>
      <center id='A2CA7E933E'><center id='A2CA7E933E'><tfoot id='A2CA7E933E'></tfoot></center><abbr id='A2CA7E933E'><dir id='A2CA7E933E'><tfoot id='A2CA7E933E'></tfoot><noframes id='A2CA7E933E'>

    • <optgroup id='A2CA7E933E'><strike id='A2CA7E933E'><sup id='A2CA7E933E'></sup></strike><code id='A2CA7E933E'></code></optgroup>
        1. <b id='A2CA7E933E'><label id='A2CA7E933E'><select id='A2CA7E933E'><dt id='A2CA7E933E'><span id='A2CA7E933E'></span></dt></select></label></b><u id='A2CA7E933E'></u>
          <i id='A2CA7E933E'><strike id='A2CA7E933E'><tt id='A2CA7E933E'><pre id='A2CA7E933E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:explore    - browse:5812

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus